/C O R R E C T I O N -- CSL Biotherapies, Inc./

               /C O R R E C T I O N -- CSL Biotherapies, Inc./

PR Newswire

KING OF PRUSSIA, Pa., Aug. 6, 2013

In the news release, CSL Biotherapies initiates shipments of its seasonal
influenza vaccine to U.S. customers, issued 06-Aug-2013 by CSL Biotherapies,
Inc. over PR Newswire, we are advised by the company that the third paragraph,
first sentence, should read "11 million doses" rather than "10 million doses"
as originally issued inadvertently. The complete, corrected release follows:

  CSL Biotherapies initiates shipments of its seasonal influenza vaccine to
  U.S. customers

    Approximately 11 million doses to be delivered within 2 months

KING OF PRUSSIA, Pa., Aug. 6, 2013 /PRNewswire/ --CSL Biotherapies, Inc.
announced today that shipment of its seasonal influenza vaccine for the
2013-2014 season has started.

"Given the magnitude of influenza burden in the U.S. and the unpredictability
of seasonal outbreaks, timely delivery of flu vaccines is more critical now
than ever before," said Dr. Marie Mazur, Head of Worldwide Commercial
Operations, Influenza. "CSL Biotherapies is committed to addressing this
public health need by consistently delivering its influenza vaccine early to
the healthcare providers in the United States."

CSL Biotherapies will ship approximately 11 million doses of the seasonal flu
vaccine to the United States for the upcoming season. Shipment will comprise
multi-dose and pre-filled syringe presentations.

About CSL Biotherapies, Inc.
CSL Biotherapies, Inc., located in King of Prussia, PA, is the U.S.
headquarters of bioCSL. Parent company CSL Limited has manufactured influenza
vaccine in its Melbourne, Australia facility since 1968. CSL Limited has made
a $60 million (U.S.D.) investment in plant and equipment to double capacity at
its Melbourne facility, making it one of the largest vaccine manufacturing
facilities in the world. CSL-branded influenza vaccines are approved in 28
countries.

At bioCSL, delivering vaccines is our mission, protecting lives our
passion.The CSL Group, which also includes CSL Research & Development, CSL
Plasma, and CSL Behring, has more than 11,000 employees globally and operates
in 26 countries around the world.

Media Contact:
Sheila Burke
610-878-4209

SOURCE CSL Biotherapies, Inc.
 
Press spacebar to pause and continue. Press esc to stop.